

The Advancing Rheumatology Patient Care MIPS Value Pathway (MVP) Quality Measures Informational Guide

[MIPS Value Pathways \(MVPs\)](#) are the newest reporting option to fulfill MIPS reporting requirements. MVPs are designed as a subset of measures and activities for subspecialty care. With MVPs, there is a foundational layer calculated through promoting interoperability and population health measures and additional performance across three categories: quality, improvement activities, and cost. The Centers for Medicaid and Medicare Services (CMS) have signaled an intent to sunset [Traditional MIPS](#) and require MVP participation in the future but has not provided a date for this transition.

The [Advancing Rheumatology Patient Care MVP](#) focuses on the clinical theme of providing fundamental treatment and management of rheumatological conditions. Below is a summary of the quality measures available for MIPS reporting via the Advancing Rheumatology Patient Care MVP for the 2025 performance year (Jan 1, 2025 – Dec 31, 2025). Additional information on CMS requirements for both Traditional MIPS and MVPs is available on the [QPP website](#).

Measure Title	Type of Measure	Has a Benchmark?	Topped Out?
QPP130: Documentation of Current Medications in the Medical Record	Process: High priority measure	Yes	Yes
QPP134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan	Process	Yes (CQM) No (eCQM)	Yes (CQM) N/A (eCQM)
QPP176: Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy	Process	Yes	Yes
QPP177: Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	Process	Yes	Yes
QPP178: Rheumatoid Arthritis (RA): Functional Status Assessment	Process	Yes	Yes
QPP180: Rheumatoid Arthritis (RA): Glucocorticoid Management	Process	Yes	Yes
QPP487: Screening for Social Drivers of Health	Process: High priority measure	No	N/A
QPP493: Adult Immunization Status	Process	No	N/A
QPP503: Gains in Patient Activation Measure Scores at 12 Months	Outcome: High priority measure	No	N/A
*ACR12: Disease Activity Measurement for Patients with PsA	Process	Yes	No
*ACR14: Gout: Serum Urate Target	Outcome: High priority measure	Yes	No
*ACR15: Safe Hydroxychloroquine Dosing	Process: High priority measure	Yes	No

* These ACR-owned, rheumatology specific QCDR measures are exclusive to the RISE registry and only available through RISE for reporting.